1. Introduction {#sec1}
===============

Kidney disease is increasing rapidly along with the increasing prevalence of hypertension and the aging of many societies worldwide \[[@B1]\]. A decline in the glomerular filtration rate (GFR) and an increase in albuminuria, established markers of kidney function, have been reported to be risk factors for various diseases, such as cardiovascular disease (CVD) \[[@B2]--[@B7]\], heart failure \[[@B6]\], cerebrovascular disease \[[@B4]--[@B6]\], hospitalization \[[@B7], [@B8]\], death from cardiovascular causes \[[@B9]\], and all-cause mortality \[[@B5]--[@B9]\]. Accordingly, the evaluation of GFR is of increasing importance in decisions about appropriate therapeutic strategies.

Many studies have shown that deterioration of GFR was attributable to hypertension \[[@B10]--[@B13]\]---in particular, a low GFR has frequently been observed in morning hypertension \[[@B13]--[@B15]\]. In addition, several studies have suggested that morning hypertension was caused by sympathetic nerve hyperactivity \[[@B16], [@B17]\]. Consequently, antihypertensive treatment which suppresses sympathetic nerve hyperactivity might be pathophysiologically effective for preserving renal function in patients with morning hypertension, as was proven in the case of renal sympathetic nerve ablation \[[@B18]\].

Aggressive blood pressure (BP) control has been recommended in hypertensive patients with CKD \[[@B19]\]. It was reported that GFR could be preserved in association with the reduction of urinary microalbumin by antihypertensive treatment \[[@B20]\], even with doxazosin \[[@B21]\]. However, several papers have demonstrated that urinary microalbumin was reduced despite the decrease in GFR in response to antihypertensive treatments \[[@B22], [@B23]\]. It has not been clarified how an aggressive antihypertensive treatment alters the GFR and urinary microalbumin and how these two parameters are related to each other during antihypertensive treatment. Furthermore, the effects of alpha or beta adrenergic blockers on these parameters are not well understood. Our hypotheses in this study were that the GFR would increase if morning hypertension was controlled by adrenergic blockers and that the change in GFR by adrenergic blockers would be associated with the improvement of urinary microalbumin. We performed this study to examine these hypotheses.

2. Methods {#sec2}
==========

This study is a subanalysis of the Japan Morning Surge-1 (JMS-1) Study, which was conducted from August 2003 to August 2005 by 20 doctors at 16 institutions (7 primary practices, 8 hospital-based outpatient clinics, and 1 specialized university hospital) in Japan. This study was registered on 2 clinical trial registration sites: ClinicalTrials.gov: no. [NCT00285519](http://clinicaltrials.gov/ct2/results?term=00285519&Search=Search) and UMIN (University Hospital Medical Information Network) Clinical Trial Registry (UMIN-CTR): no. C000000309. The ethics committee of the internal review board of the Jichi Medical University School of Medicine, Japan, approved the protocol.

2.1. Study Design {#sec2.1}
-----------------

The study protocol and design were described in our previous publication \[[@B24]\]. Briefly, patients who had been treated with various antihypertensive agents except for alpha or beta blockers were enrolled \[[@B25]\]. All patients were randomized either to a group in which morning BP was strictly moderated by a bedtime administration of doxazosin (the "added treatment group") in addition to the patients\' current hypertensive treatment regimen or to a control group whose members received no additional medication (the control group). There were no significant differences in antihypertensive agents between the groups. The randomization was carried out by an independent research center (Biomedis International, Ltd., Tokyo, Japan) by telephone. In the added treatment group, doxazosin was added just after randomization at a dose of 1 mg and titrated up to 4 mg (the recommended dose in Japan) over 3 months to achieve a morning systolic blood pressure (SBP) of less than 135 mmHg. If the morning SBP remained more than 135 mmHg at 3 months after starting doxazosin, a *β*-blocker (usually atenolol 25 mg/day) was added at bedtime. Patients in the control group continued their current medications throughout the study period even when they presented with high morning BP.

2.2. Patients {#sec2.2}
-------------

We enrolled 611 hypertensive patients whose morning SBP levels (the average of 6 readings: 2 measurements taken on each of 3 days) measured by home BP monitoring were more than 135 mmHg while being on stable antihypertensive medication for at least 3 months. They had never taken any *α*-blockers or *β*-blockers before this study. We excluded patients who had arrhythmias, a history of heart failure, orthostatic hypotension, dementia, malignancy, or chronic inflammatory disease. Written informed consent was obtained from all participants.

2.3. Blood Pressure Measurements {#sec2.3}
--------------------------------

Morning BP was measured within 1 hour after waking, and before breakfast and taking antihypertensive medication, and evening BP was measured before taking antihypertensive medication and just before going to bed. A validated oscillometric device, the HEM-705IT (Omron Healthcare Inc., Kyoto, Japan) \[[@B26]\], was used based on the Japanese Hypertension Guidelines \[[@B27]\]. BP measurements were made on each occasion in the sitting position after a 30s interval. We asked study patients to write down each home BP value, and BP analysis was conducted using the average of 2 measurements taken over each of the 3 days (6 readings in total) in the sitting position. Office BP was measured using the same monitor (HEM-705IT), and the average of 2 consecutive measurements was used for analyses.

2.4. Blood and Urine Examinations {#sec2.4}
---------------------------------

Blood and urine samples were collected in the morning in a fasting state at enrollment and at the end of the study (6 months). The urinary albumin excretion level was measured using the immunoturbidimetric method (Mitsubishi Chemical Iatron Inc., Tokyo, Japan) and expressed as the urinary albumin to creatinine ratio (UACR, mg/gCr). Both serum creatinine (s-Cr) and urine creatinine were measured by the Jaffe reaction without deproteinization and then quantified by a photometric method. The intra-/intercoefficients of variation were 1.52% and 2.48%, respectively, for the urinary albumin assay. The estimated GFR (eGFR) was calculated using a validated equation based on the Modification of Diet in Renal Disease (MDRD) study with a Japanese coefficient of 0.881: eGFR (mL/min/1.73 m^2^) = 0.881 × 186.3 × Age^−0.203^ × S-Cr^−1.154^ (if female × 0.742) \[[@B28]\]. The patients were classified into stages 1 to 5 based on the levels of GFR along with the lines of CKD staging \[[@B29]\]: stage 1, ≥90; stage 2, 60--89; stage 3, 30--59; stage 4, 15--29; stage 5, \<15 (mL/min/1.73 m^2^) for group analyses, so they had not necessarily CKD state.

2.5. Statistical Analysis {#sec2.5}
-------------------------

All primary analyses were performed on an intention-to-treat basis. Data were expressed as the mean (±SD) or a percentage. As the distribution of the UACR was highly skewed, this parameter was log-transformed before the statistical analyses. The *χ* ^2^ test was used to evaluate differences in prevalence rates. Differences in BPs, eGFR, and UACR values at enrollment and at the end of the study were compared using a paired *t*-test. Differences in BPs, eGFR, and UACR between the control group and the added treatment group at the end of the study were compared using an unpaired *t*-test. Pearson\'s correlation coefficients were used to measure the relationships between continuous measures. Multiple linear regression analyses were performed to analyze the association between changes in the eGFR and UACR, adjusting for significant covariates \[[@B30]\] including body mass index (BMI), current smoking, drinking habits, diabetes mellitus, hyperlipidemia, change in morning SBP (SBP at the 6th month minus the baseline value), eGFR at baseline, and the use of renin angiotensin system inhibitors. Age and gender were not included because the MDRD equation includes these two parameters. The Kruskal Wallis test for the change in eGFR and UACR, and one-way analysis of variance for the change in morning SBP were performed to detect differences among different CKD stages. Associations/differences with a *P* value less than 0.05 (two-tailed) were considered to be statistically significant. All statistical analyses were performed with SPSS version 11 software (SPSS Inc., Chicago, IL).

3. Results {#sec3}
==========

The randomization was successfully conducted and the baseline characteristics (except for hyperlipidemia), BPs, s-Cr, and eGFR, were similar between the control and the added treatment groups ([Table 1](#tab1){ref-type="table"}). The mean dose of doxazosin at the end of the study was 3.4 ± 1.1 mg/day. A *β*-blocker (atenolol 25 mg/day for 154 patients or bisoprolol 5 mg/day for 1 patient) was added to 155 patients (50.3%) of the added treatment group because their morning SBPs did not reach the target level of 135 mmHg or less with doxazosin alone during the first 3 months of treatment after randomization.

3.1. Changes in BP, eGFR, and UACR {#sec3.1}
----------------------------------

The morning and evening SBP decreased significantly more in the added treatment group than in the control group (morning SBP: −13.7 versus −5.2 mmHg, *P* \< 0.01; evening SBP: −6.7 versus −3.0 mmHg, *P* = 0.048) ([Table 2](#tab2){ref-type="table"}). Detailed results of the BP changes are described in our main paper \[[@B25]\].

eGFR was significantly decreased in the added treatment group and the control group from the baseline to 6 months ([Table 2](#tab2){ref-type="table"}). However, the extent of the change in eGFR (the value at 6th months minus the baseline value) was significantly greater in the added treatment group than in the control group (−3.83 versus −1.08 mL/min/1.73 m^2^, *P* = 0.001).

The UACR was also significantly reduced in the added treatment group, and the median differences in UACR were −3.4 in the added treatment group and 0.0 mg/gCr in the control group (*P* \< 0.001) from the baseline to the end of the study ([Table 2](#tab2){ref-type="table"}).

The change in eGFR and the change in UACR were significantly associated with the use of doxazosin, and these associations were independent of changes in morning SBP and several other covariates ([Table 3](#tab3){ref-type="table"}). The results were almost identical even after eliminating the four outliers of the change in eGFR or UACR (change in eGFR: *β* = −0.124, *P* = 0.003 for use of doxazosin; *β* = 0.063, *P* = 0.047 for change in morning systolic BP; change in UACR: *β* = −0.223, *P* \< 0.001, for use of doxazosin; *β* = 0.204, *P* \< 0.001 for change in morning systolic BP).

3.2. Association of the Changes in eGFR and UACR {#sec3.2}
------------------------------------------------

In univariate analyses, the changes in eGFR from the baseline to the end of the study were associated with the change in UACR in the added treatment group (*r* = 0.18, *P* = 0.002), but not in the control group (*r* = 0.04, *P* = 0.52). In multivariable analyses adjusting for hyperlipidemia, diabetes mellitus, smoking, drinking, and changes in morning SBP and eGFR at baseline, these relationships remained significant ([Table 4](#tab4){ref-type="table"}). The results were almost identical even after eliminating the four outliers of the change in eGFR or UACR (*β* = 0.196, *P* = 0.002 in the added treatment group; *β* = −0.002, *P* = 0.967 in the control group). When the data of CKD stage 1 were excluded, the results were essentially the same (*r* = 0.16, *P* = 0.033 in the added treatment group; *r* = 0.04, *P* = 0.55 in the control group).

3.3. Change in eGFR by CKD Stages {#sec3.3}
---------------------------------

Next, the change in eGFR was separately analyzed by CKD stages 1 to 4. [Table 5](#tab5){ref-type="table"} shows the extent of changes in eGFR at each CKD stage. In the control group, there were no significant differences of the change in eGFR between the different stages (*P* = 0.13). In the added treatment group, eGFR was significantly more decreased in stage 1 than in stages 2 to 4 (*P* = 0.002).

3.4. Change in UACR and Morning SBP at Each CKD Stage {#sec3.4}
-----------------------------------------------------

The change in UACR and morning SBP were also separately analyzed at each CKD stage. There were no significant differences in the changes in UACR and morning SBP between different stages in either the added treatment group (*P* = 0.22, *P* = 0.55) or control group (*P* = 0.36, *P* = 0.39), respectively ([Table 5](#tab5){ref-type="table"}).

4. Discussion {#sec4}
=============

In this study, eGFR and UACR were significantly reduced by adrenergic blockers in patients with morning hypertension. The change in eGFR was significantly and independently associated with the change in UACR in the added treatment group. Our findings may help to clarify the renal effects of antihypertensive medication, especially antiadrenergic medication. In addition, the clinical significance of this study is that UACR was improved even though the eGFR was slightly reduced by adding antihypertensive medication.

4.1. Antihypertensive Therapy and Change in eGFR {#sec4.1}
------------------------------------------------

In the present study, eGFR was reduced by adrenergic blockers over the 6-month treatment period. Several studies have demonstrated that eGFR can be reduced with calcium channel blockers, diuretics \[[@B22], [@B31]\], and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers \[[@B32]\]. A Japanese study showed that a bedtime dose of doxazosin controlled morning BP but reduced eGFR \[[@B33]\]. However, the lack of a control group in that study prevented a definitive conclusion about the effect of doxazosin on the reduction in eGFR \[[@B33]\]. In the present study, eGFR was significantly reduced in the added treatment group compared with the control group, and the change in eGFR was significantly and independently associated with the use of doxazosin and the change in morning SBP, respectively. These results indicate that the reduction of eGFR was attributable to the BP reduction and doxazosin per se. One possible explanation for the reduction in eGFR is that it was due to a reduction in intraglomerular pressure induced by the decrease in systemic BP. The blocking of the systemic and renal sympathetic nervous system may have reduced GFR by dilating the renal arteries, which may thereby have protected the kidney.

4.2. The Relationship between the Change in eGFR and Change in UACR {#sec4.2}
-------------------------------------------------------------------

In the present study, an independent and positive relationship between the change in eGFR and the UACR was observed in the added treatment group, but not in the control group. According to several studies, the hemodynamic load is the main determinant of the reduction in UACR \[[@B34]--[@B36]\] and GFR \[[@B37]\] in hypertension. BP reduction by antihypertensive treatments could unload the pressure in the renal glomeruli, which would contribute to a reduction in eGFR and UACR. Therefore, the reduction in eGFR by 6-month administration of adrenergic blockers could be due to unloading of the renal glomeruli.

4.3. Change in eGFR, UACR, and Morning SBP at Each CKD Stage {#sec4.3}
------------------------------------------------------------

When the change in eGFR was separately analyzed by CKD stage, the extent of the change in eGFR in the added treatment group was significantly greater in stage 1 than in the other stages. No such difference was seen in the control group. The mean reduction in eGFR was 7 (mL/min/1.73 m^2^) in stage 1 and less than 3 (mL/min/1.73 m^2^) in stages 2 to 4 in the added treatment group. However, these small changes were not clinically significant. To the best of our knowledge, there has been no report showing that the change in eGFR due to antihypertensive treatment differs according to CKD stage. When the changes in UACR were similarly analyzed, no differences were seen among stages. Therefore, these findings suggest that the reduction in eGFR along with the reduction in UACR by adrenergic blockers would not require special attention, at least in the short term. In addition, it is speculated that the effects of the change in morning SBP on eGFR were different by the state of eGFR at the baseline.

4.4. The Effect of Alpha Blocker Doxazosin on the Renal Function {#sec4.4}
----------------------------------------------------------------

The alpha blocker has shown the renoprotective beyond the blood pressure lowering effect \[[@B38]\]. Efferent glomerular arteriolar vasoconstriction in response to endogenous norepinephrine is mediated by *α* ~1~ adrenergic receptor, and this mechanism is cause of exaggerated in UACR \[[@B39]\]. The doxazosin has the ability to preserve renal autoregulation of renal blood flow and the observation of unaltered intraglomerular pressure. These results indicated that doxazosin has major preglomerular dilatory effects and reduces postglomerular resistance.

4.5. Study Limitations {#sec4.5}
----------------------

There were several limitations in the present study. First, we could not employ the inulin clearance method, the gold standard for the measurement of GFR. Second, the MDRD equation could have underestimated the GFR, especially above 60 mL/min/1.73 m^2^. However, it has been shown that an eGFR over 60 mL/min/1.73 m^2^ can predict mortality \[[@B40], [@B41]\] and cardiorenal events \[[@B41]\] similar to an eGFR below 60 mL/min/1.73 m^2^. In addition, the change in eGFR reflects the accurate renal functional change even in the patients with eGFR over 60 mL/min/1.73 m^2^ \[[@B42]\]. Therefore, the change in eGFR in the patients with eGFR over 60 mL/min/1.73 m^2^ achieved some positive results. Indeed, the change of eGFR in CKD stage 1 might be within the error range of the MDRD equation or the effect of regression to the mean. However, the relation between the change in eGFR and that in UACR remained even when the results for patients with CKD stage 1 were eliminated. Therefore, we stand by our conclusion that a reduction of eGFR induced by adrenergic blockers does not require special attention in the short term. Third, the correlation between the change in eGFR and the change in UACR was relatively weak because of the heterogeneity of the patients\' backgrounds. Fourth, the long-term effect of doxazosin on eGFR could not be clarified in this study. However, it has been shown that different antihypertensive combination therapies (a calcium-channel blocker plus an angiotensin converting-enzyme inhibitor (ACE-I) versus a diuretic plus an ACE-I) are associated with different levels of reduction of eGFR over a 3-month period, and after 3 months eGFR shows a gradual and parallel decline in both drug regimens \[[@B43]\]. Therefore, some positive results are also observed at sixth months. Fifth, the associations between the use of doxazosin and the change in eGFR or UACR were relatively weak. These weak associations are attributable to large differences in response to adrenergic blockers among individuals.

This study is a subanalysis of the JMS-1 Study; therefore, several table data of baseline were overlapped in a previous paper.

5. Conclusion {#sec5}
=============

In patients with morning hypertension, both eGFR and UACR were reduced by the additional use of adrenergic blockers. These reductions were significantly and independently associated with the use of doxazosin and the reduction in SBP. The reduction of eGFR was significantly associated with that in UACR. In addition, the reduction of eGFR by the adrenergic blockers was slight and exclusively seen in the CKD stage 1 patients. These results indicate that the reduction of eGFR induced by adrenergic blockers does not require special attention in the short term and could predict an improvement of urinary albumin excretion in patients with morning hypertension.
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###### 

Baseline characteristics of patients.

                                                 Added treatment group (*n* = 308)   Control group (*n* = 303)   *P* value
  ---------------------------------------------- ----------------------------------- --------------------------- -----------
  Age (years)                                    70.2 ± 9.2                          70.1 ± 10.0                 0.88
  Male (%)                                       45.1                                43.6                        0.76
  Body mass index (kg/m^2^)                      24.1 ± 3.3                          24.2 ± 3.6                  0.82
  Duration of hypertension (years)               11.5 ± 9.6                          11.3 ± 8.7                  0.74
  Duration of hypertensive therapy (years)       8.6 ± 8.3                           8.0 ± 7.1                   0.34
  Current smokers (%)                            19.2                                18.8                        1.00
  Habitual drinkers (%)                          34.1                                30.0                        0.32
  Diabetes or impaired glucose tolerance (%)     15.3                                16.5                        0.76
  Hyperlipidemia (%)                             32.5                                40.9                        0.04
  Number of antihypertensive drugs               1.6 ± 0.8                           1.6 ± 0.7                   0.71
  Calcium channel blockers (%)                   66.6                                65.6                        0.82
  Angiotensin-converting enzyme inhibitors (%)   13.1                                15.6                        0.37
  Angiotensin II receptor blockers (%)           60.3                                57.5                        0.54
  Diuretics (%)                                  22.0                                21.9                        0.93
  Oral drugs for diabetes mellitus (%)           9.5                                 7.6                         0.51
  Medication for hyperlipidemia (%)              15.1                                13.6                        0.62
  Office SBP (mmHg)                              157 ± 18                            156 ± 19                    0.43
  Office DBP (mmHg)                              83 ± 11                             82 ± 12                     0.92
  Office pulse rate (bpm)                        73 ± 18                             72 ± 17                     0.11

Data are shown as the means ± SD. Urinary albumin \[values are\] expressed as the median \[\] (25% value, 75% value). BP: blood pressure; bpm: beats per minute; SBP: systolic blood pressure; DBP: diastolic blood pressure.

###### 

Blood pressure and renal functional parameter changes during 6 months.

                                     Added treatment group (*n* = 308)   Control group (*n* = 303)                       
  ---------------------------------- ----------------------------------- --------------------------- ------------------- -------------------
  Morning SBP (mmHg)                 153 ± 13                            140 ± 15^∗∗,††^             151 ± 15            146 ± 16\*\*
  Morning DBP (mmHg)                 82 ± 10                             73 ± 10^∗∗,††^              82 ± 11             80 ± 11\*\*
  Evening SBP (mmHg)                 140 ± 14                            133 ± 15^∗∗,††^             140 ± 17            137 ± 15\*\*
  Evening DBP (mmHg)                 75 ± 10                             69 ± 10^∗∗,††^              76 ± 11             74 ± 10\*\*
  Estimated GFR (mL/min/1.73 m^2^)   84.1 ± 21.1                         80.3 ± 19.3\*\*             82.0 ± 18.9         80.9 ± 19.9\*
  Creatinine (mg/dL)                 0.79 ± 0.27                         0.82 ± 0.29\*\*             0.80 ± 0.25         0.82 ± 0.28\*
  UACR (mg/gCr)                      23.0 (11.4--63.1)                   14.7  (8.2--35.8)^∗∗,†^     21.0 (10.7--53.2)   19.4 (11.5--53.6)

Data are shown as the means ± SD. UACR is expressed as the median values (25% value--75% value). BP: blood pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure; GFR: glomerular filtration rate; UACR: urinary albumin/creatinine ratio.

 \**P* \< 0.05, \*\**P* \< 0.001 versus baseline in each group: ^†^ *P* \< 0.05, ^††^ *P* \< 0.001 versus the 6th month in the control group.

###### 

Factors associated with change in eGFR and UACR.

  Variable                                                   Change in eGFR (6th month minus baseline)   Change in UACR (6th month minus baseline)            
  ---------------------------------------------------------- ------------------------------------------- ------------------------------------------- -------- ---------
  Use of doxazosin (use = 1, no use = 0)                     −0.107                                      0.012                                       −0.178   \<0.001
  Change in morning systolic BP (6th month minus baseline)   0.085                                       0.045                                       0.251    \<0.001
  Adjusted *R* ^2^                                           0.101                                       0.117                                                

Adjustments were made for body mass index, hyperlipidemia (Yes = 1; No = 0), diabetes mellitus (Yes = 1; No = 0), smoking habit (Yes = 1; No = 0), drinking habit (Yes = 1; No = 0), and change in morning systolic BP.

eGFR: estimated glomerular filtration rate. UACR: urinary albumin to creatinine ratio. BP: blood pressure. *R* ^2^: determination coefficient.

###### 

Factors associated with change in eGFR.

  Variable                                    Change in UACR (6th month minus baseline)                    
  ------------------------------------------- ------------------------------------------- ------- -------- -------
  Change in eGFR (6th month minus baseline)   0.198                                       0.001   −0.002   0.966
  Adjusted *R* ^2^                            0.093                                       0.115            

Adjustments were made for body mass index, hyperlipidemia (Yes = 1; No = 0), diabetes mellitus (Yes = 1; No = 0), smoking habit (Yes = 1; No = 0), drinking habit (Yes = 1; No = 0), change in morning systolic BP, eGFR at baseline, and the use of renin angiotensin system inhibitors.

UACR: urinary albumin to creatinine ratio. eGFR: estimated glomerular filtration rate. BP: blood pressure. *R* ^2^: determination coefficient.

###### 

Change in eGFR, UACR and morning SBP at each CKD stage.

  CKD stage           Change in eGFR (6th month minus baseline)   Change in UACR (6th month minus baseline)   Change in morning SBP (6th month minus baseline)                                  
  ------------------- ------------------------------------------- ------------------------------------------- -------------------------------------------------- ------------------- ---------- -----------
  Stage 1             −6.4 ± 15.5                                 −2.0 ± 9.8                                  −4.3 (−16.9, 0.0)                                  −0.05 (−6.7, 4.4)   −14 ± 14   −5.3 ± 12
  Stage 2             −2.5 ± 7.5                                  −0.4 ± 7.9                                  −3.2 (−20.8, 0.0)                                  0 (−7.3, 8.5)       −12 ± 14   −3.2 ± 15
  Stage 3 + stage 4   −2.0 ± 4.3                                  −1.5 ± 5.8                                  0 (−27.0, 1.1)                                     0 (−19.2, 13.9)     −12 ± 12   −5.5 ± 13
  *P* value           0.002                                       0.13                                        0.22                                               0.36                0.55       0.39

Changes in eGFR are shown as the means ± SD. Changes in UACR are expressed as the median values (25% value, 75% value). eGFR: estimated glomerular filtration rate; UACR: urinary albumin/creatinine ratio; CKD: chronic kidney disease; SBP: systolic blood pressure.

The numbers of patients per CKD stage are 111, 166, and 31 for CKD stages 1, 2, and 3 + 4 in the added treatment group and 104, 172, and 26 for these stages in the control group, respectively. The *P* values were calculated by the Kruskal Wallis test for the change in eGFR and UACR and one-way analysis of variance for the change in morning SBP.
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